Center-Authored Papers

Filters: Author is Liu, Glenn  [Clear All Filters]
2008
Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, Lathia C, Xia C, Petrenciuc O, Hingorani SR et al..  2008.  A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(15):4836-42. Abstract
2013
Hussain M, Tangen CM, Berry DL, Higano CS, Crawford DE, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ et al..  2013.  Intermittent versus continuous androgen deprivation in prostate cancer.. The New England journal of medicine. 368(14):1314-25. Abstract
2015
Hussain M, Rathkopf D, Liu G, Armstrong A, Kelly WK, Ferrari A, Hainsworth J, Joshi A, Hozak RR, Yang L et al..  2015.  A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.. European journal of cancer (Oxford, England : 1990). 51(13):1714-24. Abstract
2016
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN et al..  2016.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Alumkal JJ, Higano CS, Chow Maneval E, Bandekar R et al..  2016.  Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.. European urology. Abstract